Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy.

Norris AM, Gentry M, Peehl DM, D'Agostino R Jr, Scarpinato KD.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):57-64. doi: 10.1158/1055-9965.EPI-08-0377.

2.

Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.

Norris AM, Woodruff RD, D'Agostino RB Jr, Clodfelter JE, Scarpinato KD.

Prostate. 2007 Feb 1;67(2):214-25.

PMID:
17044039
3.

Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel.

Shia J, Tang LH, Vakiani E, Guillem JG, Stadler ZK, Soslow RA, Katabi N, Weiser MR, Paty PB, Temple LK, Nash GM, Wong WD, Offit K, Klimstra DS.

Am J Surg Pathol. 2009 Nov;33(11):1639-45. doi: 10.1097/PAS.0b013e3181b15aa2. Erratum in: Am J Surg Pathol. 2010 Mar;34(3):432.

PMID:
19701074
4.

Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells.

Fukuhara S, Chang I, Mitsui Y, Chiyomaru T, Yamamura S, Majid S, Saini S, Deng G, Gill A, Wong DK, Shiina H, Nonomura N, Lau YF, Dahiya R, Tanaka Y.

Oncotarget. 2015 Jun 30;6(18):16341-51.

5.

Reduced Pms2 expression in non-neoplastic flat mucosa from patients with colon cancer correlates with reduced apoptosis competence.

Bernstein H, Prasad A, Holubec H, Bernstein C, Payne CM, Ramsey L, Dvorakova K, Wilson M, Warneke JA, Garewal H.

Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):166-72.

PMID:
16785784
6.

Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.

Hicks SC, Ward RL, Hawkins NJ.

Pathology. 2011 Jan;43(1):84-5; author reply 85-6. doi: 10.1097/PAT.0b013e3283410b26. No abstract available.

PMID:
21240077
7.

Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.

Langeberg WJ, Kwon EM, Koopmeiners JS, Ostrander EA, Stanford JL.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):258-64. doi: 10.1158/1055-9965.EPI-09-0800.

8.

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.

Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, Ittmann MM, Lark AL, Madden JF, Hartman A, Weiss G, Castaños-Vélez E.

J Urol. 2010 Jul;184(1):149-56. doi: 10.1016/j.juro.2010.03.012.

PMID:
20478579
9.

Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation.

Gill S, Lindor NM, Burgart LJ, Smalley R, Leontovich O, French AJ, Goldberg RM, Sargent DJ, Jass JR, Hopper JL, Jenkins MA, Young J, Barker MA, Walsh MD, Ruszkiewicz AR, Thibodeau SN.

Clin Cancer Res. 2005 Sep 15;11(18):6466-71.

10.

Improved survival with an intact DNA mismatch repair system in endometrial cancer.

Cohn DE, Frankel WL, Resnick KE, Zanagnolo VL, Copeland LJ, Hampel H, Kelbick N, Morrison CD, Fowler JM.

Obstet Gynecol. 2006 Nov;108(5):1208-15.

PMID:
17077244
11.

Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy?

Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2002 Dec;168(6):2510-5.

PMID:
12441951
13.

Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.

Hashimoto T, Yoshioka K, Nagao G, Nakagami Y, Ohno Y, Horiguchi Y, Namiki K, Nakashima J, Tachibana M.

Int J Urol. 2015 Feb;22(2):188-93. doi: 10.1111/iju.12624.

14.

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.

Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR.

J Urol. 2005 Jun;173(6):1938-42. Erratum in: J Urol. 2006 Jun;175(6):2369.

15.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x.

16.

Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.

Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC Jr; SEARCH Database Study Group..

J Urol. 2003 Jun;169(6):2136-41.

PMID:
12771735
17.
19.

Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.

Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, Huland H, Karakiewicz PI.

J Urol. 2009 Feb;181(2):601-7; discussion 607-8. doi: 10.1016/j.juro.2008.10.033.

PMID:
19084864
20.

Colorectal cancer in Iran: immunohistochemical profiles of four mismatch repair proteins.

Molaei M, Mansoori BK, Ghiasi S, Khatami F, Attarian H, Zali M.

Int J Colorectal Dis. 2010 Jan;25(1):63-9. doi: 10.1007/s00384-009-0784-1.

PMID:
19707776
Items per page

Supplemental Content

Support Center